WHERE DOES THE MONEY GO?

USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.

2020 - 2023

INSTITUTION:

CHIEF RESEARCHER:

Peter MacCallum Cancer Centre

A/Prof. Paul James

Genomic testing will be used to identify women who can benefit the most from preventative strategies. Outcomes from this study will lead to the implementation of personalised risk management.

The trial will compare the current standard of care with a personalised assessment of the risk of breast and ovarian cancer that includes 'single gene' testing, family history, personal risk factors and research genomic testing (PRS).

Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre
USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.